Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulgent Genetics, Inc. - Common Stock (NQ: FLGT )

16.98 -0.50 (-2.86%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 569,817
Open 17.48
Bid (Size) 16.75 (10)
Ask (Size) 17.33 (13)
Prev. Close 17.48
Today's Range 16.75 - 17.49
52wk Range 14.57 - 25.11
Shares Outstanding 29,926,846
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Fulgent Genetics Revenue Tops Estimates
Fulgent Genetics exceeded expectations in the fourth quarter of 2024, showcasing robust revenue growth and a GAAP loss. 
Via The Motley Fool
Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire

Performance

YTD
-7.82%
-7.82%
1 Month
+5.07%
+5.07%
3 Month
-15.65%
-15.65%
6 Month
-21.93%
-21.93%
1 Year
-25.40%
-25.40%

More News

Read More
Earnings Scheduled For February 28, 2025
Via Benzinga
Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025
From Fulgent Genetics, Inc.
Via Business Wire
Uncovering Potential: Fulgent Genetics's Earnings Preview
Via Benzinga
Earnings Preview: Fulgent Genetics
Via Benzinga
Fulgent Reports Third Quarter 2024 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent to Participate in Upcoming Conferences
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Reports Second Quarter 2024 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer
From Fulgent Pharma
Via Business Wire
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
From Fulgent Pharma
Via Business Wire
Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
From Fulgent Pharma
Via Business Wire
FLGT Stock Earnings: Fulgent Genetics Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Fulgent Reports First Quarter 2024 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024
From Fulgent Genetics, Inc.
Via Business Wire
The 3 Best Digital Health Stocks for Personalized Medicine
Via InvestorPlace
Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting
From Fulgent Genetics, Inc.
Via Business Wire
Earnings Scheduled For November 3, 2023
Via Benzinga
Fulgent Reports Third Quarter 2023 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.